ICU Medical ICUI
- Market cap
- $4.2B
- PE
- 141×
- 10y median 57.8×
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 1.9×
- EV/EBIT
- 45.9×
- Revenue, 12 months
- $2.2B
- −9% on a year ago
- Net margin
- 1.4%
- Free cash flow yield
- 3.7%
ICU Medical trades at 141× trailing earnings, pricier than 84% of the last ten years. Revenue was $2.2B over the last twelve months, down 9% on a year earlier with a 1% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $553.3M−8% | $587.9M+2% | $566.7M−0% | $596.5M+9% | $589.1M+7% | $629.8M+7% | $604.7M+7% | $548.9M−8% | $537M−9% | $540.7M−14% | $530.2M−12% | $551.7M+1% | |
| Cost of revenue | $369.4M−10% | $416.3M+3% | $381.4M+1% | $389M+9% | $384.3M+4% | $402.5M−3% | $394.6M+4% | $340.8M−12% | $336.1M−13% | $337.7M−16% | $324M−18% | $316.6M−7% |
| Gross profit | $183.9M−1% | $171.6M−2% | $185.2M−4% | $207.4M+8% | $204.9M+11% | $227.3M+32% | $210.1M+13% | $208.1M+0% | $200.9M−2% | $203M−11% | $206.2M−2% | $235.1M+13% |
| R&D | $20.9M−10% | $22.4M−4% | $21.8M+11% | $23.4M+5% | $21M+1% | $22.4M−0% | $23.3M+7% | $21.9M−7% | $21.3M+1% | $21.1M−6% | $21.3M−9% | $22.7M+4% |
| SG&A | $148.6M−3% | $154.6M+8% | $157.7M+3% | $159.5M+6% | $162.7M+10% | $158.8M+3% | $157.2M−0% | $159.4M−0% | $152.8M−6% | $155.8M−2% | $154.6M−2% | $151.9M−5% |
| $22.9M | −$12.2M+5388% | −$10.7M | $7.7M+179% | $8.2M−64% | $37.7M | $12.9M | $10.6M+38% | $13.7M+67% | $5.6M−85% | $13.6M+5% | $39.1M+270% | |
| Interest expense | $24.2M+36% | $31.9M+30% | $23.8M+6% | $23.8M−1% | $24.7M+2% | $34.2M+7% | $22M−7% | $20.5M−14% | $19.8M−20% | $30.9M−10% | $16.5M−25% | $15.7M−23% |
| Pre-tax income | −$5.4M−75% | −$36.7M+71% | −$36.8M+175% | −$19.5M−15% | −$17.9M+234% | $8.2M | −$10.9M−70% | $33.7M | −$2.5M−86% | −$15.9M | −$4M−64% | $23.1M−31% |
| −$12.6M+56% | −$19.5M+231% | $2.7M | $1.9M | $15.1M | $32M | $4.6M+69% | $1.2M−37% | −$658K | −$2.7M | −$34.7M | $7.1M+500% | |
| Net income | $7.2M | −$17.1M+10% | −$39.5M+302% | −$21.4M+116% | −$33M | −$23.8M+39% | −$15.5M−61% | $35.3M | −$3.4M−90% | −$15.7M−34% | $30.1M | $19.1M−46% |
| $0.30 | −$0.71+9% | −$1.63+298% | −$0.88+115% | −$1.35 | −$0.97+37% | −$0.63−61% | $1.43 | −$0.14−90% | −$0.64−34% | $1.20 | $0.76−47% | |
| 24.4M+2% | 24.1M+1% | 24.2M+1% | 24.4M+1% | 24.4M+0% | 24.5M+2% | 24.5M+1% | 24.7M+1% | 24.7M+1% | 24.7M+1% | 25.2M+3% | 25M+1% |
EPS, diluted: 12 periods, Q4 FY08 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 13 periods, Q4 FY08 to Q4 FY21: share-days: the 12-month average less the 9-month, weighted by days. 5 periods, Q4 FY18 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Instruments & Supplies nearest ICU Medical's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| ICUIICU Medical | $4.2B | 141× | 57.8× | 1.9× | −9% | 1.4% | |
| BMIBadger Meter | $4.4B | 35.3× | 47.6× | 5.0× | −2% | 14.3% | |
| NVSTEnvista | $3.8B | 40.7× | 27.9× | 1.3× | +12% | 3.3% | |
| VNTVontier | $4.6B | 14.3× | 13.5× | 1.5× | +1% | 11.3% | |
| HAEHaemonetics | $5.4B | 58.1× | 51.6× | 4.0× | +0% | 7.1% | |
| WRBYWarby Parker | $3.2B | 370× | 366× | 3.5× | +11% | 0.8% | |
| MMSIMerit Medical Systems | $5.6B | 38.6× | 57.5× | 3.5× | +10% | 9.2% | |
| ATRCAtriCure | $3B | 281× | 58.4× | 5.3× | +14% | 1.9% | |
| MSAMSA Safety | $7B | 22.7× | 36.3× | 3.6× | +6% | 16.1% | |
| UFPTUFP Technologies | $2.3B | 31.9× | 25.6× | 3.6× | +7% | 11.4% | |
| INSPInspire Medical Systems | $2.1B | 15.4× | 58.0× | 2.3× | +4% | 15.0% | |
| Peer median | $4.1B | 36.9× | 49.6× | 3.6× | +7% | 10.3% |
Investors who own it
Investors we follow who held ICU Medical at the end of Jun 30, 2026, from their 13F filings.
- Reinhart PartnersReinhart Partners1.1% of portfolionew
More on ICU Medical
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Its groups
About
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .